diclofenac has been researched along with Malignant Melanoma in 7 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 5.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Melanoma is an aggressive cutaneous cancer, whose incidence is growing in recent years, especially in the younger population." | 5.39 | Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines. ( Albano, F; Arcucci, A; De Vendittis, E; Granato, G; Montagnani, S; Romano, S; Ruocco, MR, 2013) |
| "Epithelial non-melanoma skin cancer (NMSC) like actinic keratosis (AK), Bowen's disease (BD) and basal cell carcinoma (BCC) represent the most common malignancies in the fair skinned population." | 2.46 | Taking treatment decisions in non-melanoma skin cancer--the place for topical photodynamic therapy (PDT). ( Sidoroff, A; Thaler, P, 2010) |
| "Melanoma is characterized by high glucose uptake, partially mediated through elevated pyruvate dehydrogenase kinase (PDK), making PDK a potential treatment target in melanoma." | 1.72 | Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities. ( Bakker, BM; de Jong, S; Evers, B; Jalving, M; Tiersma, JF, 2022) |
| "Potentially, non-melanoma skin cancer in humans may be prevented with these agents with few adverse effects." | 1.39 | Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. ( Burcharth, J; Pommergaard, HC; Raskov, H; Rosenberg, J, 2013) |
| "Melanoma is an aggressive cutaneous cancer, whose incidence is growing in recent years, especially in the younger population." | 1.39 | Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines. ( Albano, F; Arcucci, A; De Vendittis, E; Granato, G; Montagnani, S; Romano, S; Ruocco, MR, 2013) |
| "Cotreatment with sorafenib and diclofenac interrupts a positive feedback signaling loop involving extracellular signal-regulated kinase, cellular phospholipase A2, and COX." | 1.38 | Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. ( Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Tiersma, JF | 1 |
| Evers, B | 1 |
| Bakker, BM | 1 |
| Jalving, M | 1 |
| de Jong, S | 1 |
| Brummer, C | 1 |
| Faerber, S | 1 |
| Bruss, C | 1 |
| Blank, C | 1 |
| Lacroix, R | 1 |
| Haferkamp, S | 1 |
| Herr, W | 1 |
| Kreutz, M | 2 |
| Renner, K | 2 |
| Gottfried, E | 1 |
| Lang, SA | 1 |
| Bosserhoff, A | 1 |
| Gronwald, W | 1 |
| Rehli, M | 1 |
| Einhell, S | 1 |
| Gedig, I | 1 |
| Singer, K | 1 |
| Seilbeck, A | 1 |
| Mackensen, A | 1 |
| Grauer, O | 1 |
| Hau, P | 1 |
| Dettmer, K | 1 |
| Andreesen, R | 1 |
| Oefner, PJ | 1 |
| Pommergaard, HC | 1 |
| Burcharth, J | 1 |
| Rosenberg, J | 1 |
| Raskov, H | 1 |
| Sidoroff, A | 1 |
| Thaler, P | 1 |
| Roller, DG | 1 |
| Axelrod, M | 1 |
| Capaldo, BJ | 1 |
| Jensen, K | 1 |
| Mackey, A | 1 |
| Weber, MJ | 1 |
| Gioeli, D | 1 |
| Albano, F | 1 |
| Arcucci, A | 1 |
| Granato, G | 1 |
| Romano, S | 1 |
| Montagnani, S | 1 |
| De Vendittis, E | 1 |
| Ruocco, MR | 1 |
1 review available for diclofenac and Malignant Melanoma
| Article | Year |
|---|---|
Taking treatment decisions in non-melanoma skin cancer--the place for topical photodynamic therapy (PDT).
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Dermatology; Diclofenac; Humans; M | 2010 |
6 other studies available for diclofenac and Malignant Melanoma
| Article | Year |
|---|---|
Pyruvate Dehydrogenase Kinase Inhibition by Dichloroacetate in Melanoma Cells Unveils Metabolic Vulnerabilities.
Topics: Dichloroacetic Acid; Diclofenac; Glucose; Humans; Melanoma; Pyruvate Dehydrogenase Acetyl-Transferri | 2022 |
Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2019 |
New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Carcinoma; Cell Line, Tumor; | 2013 |
Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Calcitriol; Chemoprevention; D | 2013 |
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; | 2012 |
Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biomarkers, Tumor; Caspase 9; Cell Line, Tumor; | 2013 |